GLP-1 Wegovy (semaglutide) and Eli Lilly's (LLY) experimental oral GLP-1 orforglipron are among the second round of ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on ...

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for ...